Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia

Published:2010-12-03 Issue:3 Volume:25 Page:473-478
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rossignol J,Michallet A-S,Oberic L,Picard M,Garon A,Willekens C,Dulery R,Leleu X,Cazin B,Ysebaert L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010278.pdf

Reference15 articles.

1. Hamblin TJ . Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230–239.

2. Karlsson C, Hansson L, Celsing F, Lundin J . Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21: 511–514.

3. Hallek M, Cheson BD, Catovsky D, Caligaris-Capio F, Dighiero G, Döhner H et al. International workshop on chronic lymphocytic leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood 2008; 111: 5446–5456.

4. Dearden C . Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008; 2008: 450–456.

5. Hall AM, Vickers MA, McLeod E, Barker RN . Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105: 2007–2015.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches;Cell Communication and Signaling;2024-02-15

2. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias;Leukemia;2023-05-18

3. Ibrutinib in combination with rituximab is highly effective in treatment of steroid refractory autoimmune hemolytic anemia;2022-12-06

4. Traitement du PTI et de l’AHAI associés aux hémopathies lymphoïdes B indolentes : faut-il traiter le clone ?;La Revue de Médecine Interne;2022-12

5. Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia;Annals of Hematology;2022-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3